BCL2L11 and cancer: For instance, ERK phosphorylation of BIM leads to RSK1/2-sensitive, βTRCP-mediated proteasomal degradation [19,20], suggesting that hyperactivation of MAP kinase signaling may enable cancer cells to suppress BIM levels and evade apoptosis.